



STATE BOARD OF OPTOMETRY
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course
 Approval Checklist

Title:

Provider Name:

- Completed Application
 - Open to all Optometrists? Yes No
 - Maintain Record Agreement? Yes No
- Correct Application Fee
- Detailed Course Summary
- Detailed Course Outline
- PowerPoint and/or other Presentation Materials
- Advertising (optional)
- CV for EACH Course Instructor
- License Verification for Each Course Instructor
 - Disciplinary History? Yes No

Receipt #	Payor ID	Beneficiary ID	Amount
1-3667	5345357	5345357	\$50



STATE BOARD OF OPTOMETRY
2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL APPLICATION

\$50 Mandatory Fee

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.

* 1 hour of CE Requested *

Course Title Hollenhorst Plaques	Course Presentation Date 6:30pm - 8:30pm 06/06/2017
Course Provider Contact Information 450 Post St, SF, CA 94102	
Provider Name Cynthia (First) Lieu (Last) (Middle)	
Provider Mailing Address Street 2100 Webster St. City San Francisco State CA Zip 94115	
Provider Email Address cliu@pacificeye.com	
Will the proposed course be open to all California licensed optometrists?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

Course Instructor Information

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

Instructor Name Jennifer (First) Sung (Last) U. (Middle)	
License Number G88754	License Type MD
Phone Number (415) 9233007	Email Address jsung@pacificeye.com

I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.

Signature of Course Provider

5/1/2017

Date

 **PACIFIC EYE
ASSOCIATES**
Our Vision is Your Sight

EVERETT AJ, M.D.
MEDICAL DISEASES OF THE
MACULA, RETINA AND VITREOUS

ARTHUR W. ALLEN, M.D.
MEDICAL DISEASES AND SURGERY OF THE
MACULA, RETINA AND VITREOUS
COMPREHENSIVE OPHTHALMOLOGY

ANNE E. FUNG, M.D.
MEDICAL DISEASES OF THE
MACULA, RETINA AND VITREOUS
COMPREHENSIVE OPHTHALMOLOGY

DAVID HEIDEN, M.D.
UVEITIS
COMPREHENSIVE OPHTHALMOLOGY

DANNY Y. LIN, M.D.
CORNEAL AND EXTERNAL DISEASE
INTRALASIK LASIK
CATARACT SURGERY
COMPREHENSIVE OPHTHALMOLOGY

EVE E. MOSCATO, M.D.
OCULOFACIAL PLASTIC SURGERY

KAREN W. OXFORD, M.D.
CORNEAL AND ANTERIOR
SEGMENT SURGERY
GENERAL OPHTHALMOLOGY

AUGUST L. READER, III, M.D.
NEURO-OPHTHALMOLOGY
CATARACT SURGERY
COMPREHENSIVE OPHTHALMOLOGY

STUART R. SEIFF, M.D.
LACRIMAL AND ORBITAL SURGERY
COSMETIC EYELID SURGERY

SCOTT C. SO, M.D.
GLAUCOMA SPECIALIST
CATARACT SURGERY
COMPREHENSIVE OPHTHALMOLOGY

JENNIFER U. SUNG, M.D.
MEDICAL DISEASES AND SURGERY OF THE
MACULA, RETINA AND VITREOUS
COMPREHENSIVE OPHTHALMOLOGY

ALI A. ZAIDI, M.D.
MEDICAL DISEASES AND SURGERY OF THE
MACULA, RETINA AND VITREOUS
COMPREHENSIVE OPHTHALMOLOGY

LAURA INGER, O.D.
COMPREHENSIVE OPTOMETRY

THOMAS KING, O.D.
COMPREHENSIVE OPTOMETRY

MARY S. KWONG, O.D.
COMPREHENSIVE OPTOMETRY

TELEPHONE
(415) 923-3007

FACSIMILE
(415) 923-6586

WEBSITE
WWW.PACIFICEYE.COM

May 1, 2017

California Board of Optometry
2450 Del Paso Road, Suite 105
Sacramento, CA 95834
(916) 575-7170

To Whom It May Concern:

Please accept my apologies for the late application. We understand that sufficient lead time is needed for the Board to review CE requests and supporting documentation.

The reason why we are submitting this application 35 days instead of the recommended 45 days before the event is because of conflicting schedules. The doctor who is presenting this course (Dr. Jennifer Sung) was away on a business conference and then I was out of the office on a business trip. This miscommunication and scheduling conflict will not occur again in the future.

Pacific Eye Associates plans to host several more CE events this year and in order to avoid this mishap from happening again in the future, I have planned out all future lectures accordingly, making sure there is enough time to submit my CE requests (at least 45 days prior to the event date.)

Sincerely,



Cynthia Lieu

Hollenhorst Plaques
Wednesday, June 7, 2017

Jennifer Sung, MD

Hollenhorst plaques are refractile, orange-yellow, atheromatous emboli in the retinal arterioles that contain cholesterol crystals and originate in the carotid artery or great vessels. They are a marker of significant carotid disease regardless of retinal symptoms. The presence of visual symptoms upon presentation does not increase the risk of death or stroke. Carotid auscultation in patients with Hollenhorst plaques increases the yield in diagnosing asymptomatic patients with significant carotid stenosis. All patients with Hollenhorst plaques, whether symptomatic or asymptomatic, should have a complete medical workup including carotid ultrasonography.

Hollenhorst Plaques
Wednesday, June 7, 2017

Jennifer Sung, MD

- I. Case Presentation
- II. Clinical signs and symptoms
- III. Examination
 - a. Ocular examination
 - b. Medical examination
- IV. Ancillary Testing
 - a. Optical Coherence Tomography
 - b. Fundus Photography
 - c. Fluorescein angiography
 - d. Carotid Ultrasonography
- V. Risk Factors
- VI. Management
- VII. Review

Case Study M.D.

HPI

- 70 year old man c/o blurred vision OD> OS for several weeks
- MVA in August 2016 with severe whiplash
- Floaters and flashes, OD
- Vision goes grey and darkens for 10 sec to 2 minutes, superior field

Past Medical History


- Denies DM, HTN, CAD, CVA
- Hx of Arthritis, elevated cholesterol, melanoma (s/p excision)
- NKDA
- Former smoker
- Fm Hx of AMD, Glaucoma, DM, CAD, MI, CVA
- Meds: Celebrex, Lovastatin, Gabapentin, baby ASA

Ocular Exam




- Va: 20/20 OU
- IOP: 23/20 mm Hg
- Anterior segment: 2+ nuclear sclerosis
- DFE: Drusen OU, ERM OU

3.14.2017


Macula Thickness : Macular Cube 512x128 OD OS




Overlay: ILM - RPE Transparency: 50 %
High-definition mode



ILM - RPE



ILM




RPE

	Central Subfield Thickness (µm)	Cube Volume (mm ³)	Cube Average Thickness (µm)
ILM - RPE	281	10.4	292




Comments
Analysis Edited: 3/14/2017 4:17 PM

Doctor's Signature
dimus4000
SW Ver: 6.0.1.24
Copyright 2012
Carl Zeiss Medtec, Inc
All Rights Reserved
Page 1 of 1


Macula Thickness : Macular Cube 512x128 OD OS




Overlay: ILM - RPE Transparency: 50 %



ILM - RPE



ILM



RPE

	Central Subfield Thickness (µm)	Cube Volume (mm ³)	Cube Average Thickness (µm)
ILM - RPE	275	10.0	279

Comments
Analysis Edited: 3/14/2017 4:17 PM

Doctor's Signature
dimus4000
SW Ver: 6.0.1.24
Copyright 2012
Carl Zeiss Medtec, Inc
All Rights Reserved
Page 1 of 1

3.14.2017



3.14.2017



More History

- Carotid ultrasound: 50-60% occlusion

Treatment

- Continue baby Aspirin.
- Monitor cholesterol level.
- Placed on Betimol BID OD

3.28.2017

- Va sc: 20/25+ OU
- IOP: 16/15 mm Hg
- Betimol BID OU
- Patient states the dark area is gone

3.28.2017



Hollenhorst Plaques: What is the Risk?

TABLE 1. BASELINE CHARACTERISTICS OF SYMPTOMATIC VS ASYMPTOMATIC PATIENTS WITH HOLLENHORST PLAQUES

BASELINE CHARACTERISTICS	SYMPTOMATIC (N=60)	ASYMPTOMATIC (N=177)	P VALUE (FISHER EXACT TEST)
Age (years)	70.7 ± 9.5	70.9 ± 9.8	.810
Gender: female/male (%)	21.7 / 78.3	39.0 / 61.0	.018*
BMI (kg/m ²)	29.5 ± 5.0	28.7 ± 7.8	.359
Hypertension (%)	56.7	69.5	.083
Diabetes mellitus (%)	18.3	26.6	.227
Hyperlipidemia (%)	58.3	55.9	.766
Current tobacco use (%)	18.3	14.1	.414
Any tobacco use (%)	74.6	61.6	.084
Coronary artery disease (%)	53.3	40.1	.097
Cerebrovascular disease (%)	23.3	23.7	1.000
Peripheral vascular disease (%)	16.7	19.8	.705
Significant carotid disease (%)	6.7	12.5	.338
Current aspirin use (%)	43.3	62.7	.010*
Current clopidogrel use (%)	1.7	5.1	.459
Current warfarin use (%)	15.0	8.5	.213
Current beta blocker use (%)	33.3	31.6	.873
Current ACE/ARB use (%)	38.3	33.3	.531
Current statin use (%)	33.3	36.7	.756

ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index.

*Statistically significant ($P < .05$).

Hollenhorst Plaques: What is the Risk?

TABLE 4. CAROTID ULTRASOUND EVALUATION RESULTS OF ASYMPTOMATIC HOLLENHORST PLAQUE PATIENTS WITH AND WITHOUT CAROTID BRUITS

MANAGEMENT AND WORKUP	NO BRUIT (N=78)	WITH BRUIT (N=29)	P VALUE (ONE-WAY ANOVA)
Carotid ultrasound performed (%)	89.7	92.9	1.000
Atherosclerosis on ultrasound (%)	95.7	100.0	.557
Stenosis >40% on ultrasound (%)	18.6	55.6	.0008*
Stenosis >69% on ultrasound (%)	4.3	37.0	.0001*
Carotid endarterectomy (%)	2.6	37.9	<.001*

*Statistically significant ($P < .05$).

Hollenhorst Plaques: What is the Risk?


TABLE 5. FOLLOW-UP DATA ON VASCULAR EVENTS IN PATIENTS WITH HOLLENHORST PLAQUES

VARIABLE	SYMPTOMATIC (N=32)	ASYMPTOMATIC (N=100)	P (FISHER EXACT TEST)
Follow-up (months) ± SD	39.6 ± 22.9	41.3 ± 21.8	.509
Combined visual events % (n)	9.4 (3)	8.0 (8)	.727
Transient ischemic attack (TIA) % (n)	12.5 (4)	7.0 (7)	.461
Stroke % (n)	6.3 (2)	7.0 (7)	1.000
Combined stroke/TIA % (n)	15.6 (5)	13.0 (13)	.769
Carotid endarterectomy % (n)	4.0 (2)	4.3 (7)	1.000
Myocardial infarction % (n)	9.4 (3)	13.0 (13)	.760
Cardiac mortality % (n)	6.3 (2)	8.0 (8)	1.000
All cause mortality % (n)	15.6 (5)	18.0 (18)	1.000
Combined stroke/TIA % (n)	15.6 (5)	13.0 (13)	.769

*Statistically significant ($P < .05$).

Take Home Message: Hollenhorst Plaques

- Males > females
- Current ASA use decreases symptoms
- Presence of carotid bruit may indicate stenosis >40%
- No significant difference in follow up vascular events or mortality in symptomatic vs asymptomatic patients (TIA, MI, CEA)
- Notify PCP for urgent follow up when Hollenhorst plaque diagnosed!



CURRICULUM VITAE

JENNIFER UNJOO SUNG

Pacific Eye Associates
2100 Webster Street, Suite 214
San Francisco, CA 94115
(415) 923-3007 (office)

jsung@pacificeye.org
retinacat@yahoo.com
(650) 762-6311 (cell)
(415) 923-6586 (fax)

POSITIONS AND EMPLOYMENT:

- 2011-present PACIFIC EYE ASSOCIATES, California Pacific Medical Center
 San Francisco, CA
- Staff Ophthalmologist
- 2001-2010 WILMER EYE INSTITUTE, Johns Hopkins University School of Medicine,
 Baltimore, MD
- Assistant Professor of Ophthalmology, Retina Division
- 2000-2001 MOORFIELDS EYE HOSPITAL/INSTITUTE OF OPHTHALMOLOGY
 London, United Kingdom
- Clinical research fellow in medical retina to Professor Alan Bird
- 1998-2000 WILLS EYE HOSPITAL, Retina Service
 Philadelphia, PA USA
- Fellow in vitreoretinal diseases
- 1995-1998 BASCOM PALMER EYE INSTITUTE, University of Miami School of Medicine
 Miami, FL USA
- Resident in ophthalmology
- 1994-1995 EVANSTON HOSPITAL
 Evanston, IL USA
- Completed internship in preliminary medicine

EDUCATION:

- 2005-2008 JOHNS HOPKINS UNIVERSITY CAREY BUSINESS SCHOOL
 Baltimore, MD
- Received M.B.A. in Medical Services Management in May 2008
- 1989-1994 NORTHWESTERN UNIVERSITY MEDICAL SCHOOL
 Chicago, IL USA
- Received M.D. in June 1994
- 1986-1989 NORTHWESTERN UNIVERSITY HONORS PROGRAM IN MEDICAL EDUCATION
 Evanston, IL USA
- B.A. in neurobiology and physiology awarded in 1989
- 1982-1986 FOX CHAPEL AREA HIGH SCHOOL
 Pittsburgh, PA USA
- National Merit Scholar
 - Pennsylvania Governor's School for the Sciences

JENNIFER U. SUNG

RESEARCH EXPERIENCE:

- 2001-2010 Wilmer Eye Institute and Department of Neuroscience, Johns Hopkins University with Peter Campochiaro, MD and Solomon Snyder, MD
Baltimore, MD
- Neuroprotective agents in retinal degenerations
 - Oxidative damage in retinal degenerations
- 2000-2001 Moorfields Eye Hospital/Institute of Ophthalmology, University College of London with Professor Alan Bird
London, United Kingdom
- Histoclinicopathological correlation of autofluorescence in ocular disorders
- 1992-1993 Howard Hughes Medical Institute Research Scholar at the National Institutes of Health in the National Eye Institute/Laboratory of Retinal Cell and Molecular Biology with Gerald J. Chader, Ph.D.
Bethesda, MD USA
- Identification of candidate genes for retinal diseases using subtraction cloning techniques
- 1990-1992 Neuroscience research with Paul A. Knepper, M.D., Ph.D. at Children's Memorial Hospital
Chicago, IL USA
- Assessment of arachnoid cell survival on differential substrata *in vitro*
- 1989-1990 Immunology research with Philip Y. Paterson, M.D. at Northwestern University Medical School
Chicago, IL USA
- Immunofluorescent studies of rat spinal cord in Experimental Allergic Encephalomyelitis (EAE)
- 1988-1989 Neuroscience research with William Klein, Ph.D. at Northwestern University Evanston, IL USA
- Effects of retinoic acid and glutamate on synaptogenesis in embryonic chick retina cultures

HONORS AND AWARDS:

- 1990 Northwestern University Baxter Research Award
1991 Northwestern University Medical Student Research Award
1992 Howard Hughes Medical Institute-National Institutes of Health Research Scholar
1997 Florida Society of Ophthalmology, selected to present at Annual Meeting
2005 Knights Templar Eye Foundation Research Grant Award
2006 NIH K12 Clinician-Scientist Award
2007 Foundation for Fighting Blindness Center Grant, Module co-Principal Investigator

PUBLICATIONS:

Oveson BC, Iwase T, Hackett SF, Lee SY, Usui S, Sedlak TW, Snyder SH, Campochiaro PA, **Sung JU**. Constituents of Bile, Bilirubin and TUDCA, Protect Against Oxidative Stress-Induced Retinal Degeneration. *J Neurochem*. 2010 Nov 3.

Campochiaro PA, Hafiz G, Channa R, Shah S, Nguyen QD, Ying H, Do D, Zimmer-Galler I, Solomon S, **Sung JU**, Syed B. Antagonism of Vascular Endothelial Growth Factor for Macular Edema Due to Retinal

JENNIFER U. SUNG

Vein Occlusions; Two Year Outcomes: Ranibizumab for Macular Edema in Vein Occlusions. *Ophthalmology*. 2010 Jul 12

Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA; READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the macula in diabetes (READ-2) study. *Ophthalmology*. 2009 Nov;116(11):2175-81.e1. Epub 2009 Aug 22. Collaborator

Browning DJ et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology*. 2008 Aug;115(8):1366-71, 1371.e1. (collaborator)

Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, **Sung JU**, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR. Ranibizumab for macular edema due to retinal vein occlusions: Implication for VEGF as a critical stimulator. *Mol Ther*. 2008 Apr;16(4):791-9

Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, Zimmer-Galler I, **Sung JU**, Haller JA. Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. *Retina*. 2007 Jun;27(5):552-6.

Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, Zimmer-Galler I, **Sung JU**, Haller JA. The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. *Trans Am Ophthalmol Soc*. 2006;104:161-6.

Shah SM, Tatlipinar S, Quinlan E, **Sung JU**, Tabandeh H, Nguyen QD, Fahmy AS, Zimmer-Galler I, Symons RC, Cedarbaum JM, Campochiaro PA. Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography. *Invest Ophthalmol Vis Sci*. 2006 Dec;47(12):5460-8.

Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, **Sung J**, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. *Am J Ophthalmol*. 2006 Dec;142(6):961-9.

Nguyen QD, Shah SM, Hafiz G, Quinlan E, **Sung J**, Chu K, Cedarbaum JM, Campochiaro PA; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. *Ophthalmology*. 2006 Sep;113(9):1522.e1-1522.e14

Margalit E, **Sung JU**, Do DV, Yohay K, Nguyen QD. Panuveitis in association with pseudotumor cerebri. *J Child Neurol*. 2005 Mar;20(3):234-6.

Do DV, Shah SM, **Sung JU**, Haller JA, Nguyen QD. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. *Am J Ophthalmol*. 2005 Apr;139(4):620-3.

Nguyen QD, Shah SM, Van Anden E, **Sung JU**, Vitale S, Campochiaro PA. Supplemental oxygen improves diabetic macular edema: a pilot study. *IOVS* 2004 Feb;45(2):617-24.

Apte RS, **Sung JU**, Bernardo C, Feuer-Greenberg E. Giant neurosensory detachments associated with disciform lesions in neovascular age related macular degeneration. *Br J Ophthalmol* 2003 Jun;87(6):795-6.

Okoye G, Zimmer J, **Sung J**, Gehlbach P, Deering T, Nambu H, Hackett S, Melia M, Esumi N, Zack DJ, Campochiaro PA. Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. 2003 *J Neuroscience*. May 15; 23(10):4164-72.

Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, J.U. **Sung JU**. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF. 11D

JENNIFER U. SUNG

(ADPEDF) in neovascular age-related macular degeneration (AMD). 2002 *Hum Gene Ther* **12** (16):2029-32.

Englebrecht NE, Aaberg TM, Jr, Lewis ML, **Sung JU**. Neovascular membranes associated with idiopathic juxtafoveal telangiectasis. 2002 *Arch Ophthalmol* **120**(3):320-4.

Takahashi K, Lou T, Saishin Y, Saishin Y, **Sung J**, Hackett S, Brazzell R, Kaleko M, Campochiaro PA. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. 2002 *Hum Gene Ther* **13**(11): 1305-16.

Sung J, Lam B, Curtin V, Tse D. Metastatic gastric carcinoma to the optic nerve. (1998) *Arch Ophthalmol* **116**:692-693

Jampol LM, **Sung JU**, Walker JD, Folk JC, Townsend-Pico WA, LowderCY, Dodds EM, Westrich D, Terry J. Choroidal neovascularization secondary to *Candida albicans* chorioretinitis. 1996 *Am J Ophthalmol* **121**:643-649.

ABSTRACTS:

Oveson B, Hackett S, Lee SY, Sedlak T, Snyder S, Campochiaro PA, and **Sung JU**. Constituents of Bile, Bilirubin and TUDCA, Protect Against Retinal Degeneration IOVS, ARVO abstract, 2010.

Sung, JU, Oveson, B, Jo, Y.-J., Shen, J., Sedlak T., Blackshaw, S, Snyder,SH, Campochiaro PA. Heme Oxygenase Pathway in Retinal Degenerations.(2009) IOVS ARVO abstract, 2009

Schulick R, Choti M, Wolfgang C, Pawlik T, Campbell K, Chang D, Edil B, Salani R, Antonik L, **Sung J**, and Cameron J. The Relationship of Hospital Volume to Outcome and Cost for Pancreaticoduodenectomy in the State of Maryland. American Surgical Association 2007 Nov (submitted)

Sung JU, Lima e Silva R, Saishin Y, Zhang M, Rogers BS, Deering TG, Aslam S, Saishin Y, Campochiaro PA. (2004) The effect of erythropoietin on hyperoxia-induced retinal degeneration and hypoxia-induced retinal neovascularization. IOVS ARVO abstract, March 15, 2004

Okoye G, Zimmer J, **Sung J**, Gehlbach P, Deering T, Nambu H, Hackett S, Melia M, Esumi N, Zack DJ, Campochiaro PA. Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. IOVS **44**: ARVO abstract #3146, March 15, 2003

Sung JU, Takahashi K, Luo T, Saishin Y, Saishin Y, Kaleko M, Hackett S, Campochiaro PA Long-term Transduction of Retinal Pigmented Epithelial (RPE) Cells With a Bovine Immuno deficiency Viral (BIV) Vector. IOVS **43**: ARVO abstract #4614, March 15, 2002

Sung JU, Dubovy SR, Stanga PE, Fitzke FW, Bird AC, Luthert PJ. Quantitative imaging of fundus autofluorescence in post-mortem human eyes with comparison to confocal scanning laser ophthalmoscope. IOVS ARVO abstract #340, March 15, 2001

Sung J, Flynn H, Jr, Ehliel F. (1998) Etiology and echographic features of choroidal folds. IOVS. **39**(4): ARVO abstract #3864, March 15, 1998

Sung JU, Mazuruk K, McCrean N, Chader GJ, and Rodriguez IR. Cloning of a novel cDNA expressed in retina and brain. 1993 IOVS. **34**(4): ARVO abstract #541, March 15, 1993.

BOOK CHAPTERS:

Sung J, Ho A. Macular pucker. Chapter in Spaeth (ed) Ophthalmic Surgery 3rd ed.

JENNIFER U. SUNG

OTHER PUBLICATIONS:

Sung JU, co-author on ophthalmology and chest/pulmonary sections of emergency medicine guide for palmtop computers. Palmtop Emergency Physician Information Database (PEPID). 1994-97.

PRESENTATIONS:

Sung JU. Is There a Role for Vitrectomy or Pharmacologic Treatment of Abnormal Vitreomacular Adhesions for Diabetic Macular Edema? (2010) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU. Steroids for Macular Edema in Vein Occlusions (2010) Macula 2010, Baltimore, MD

Sung JU. Steroids for Vein Occlusions: SCORE (2009) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU. Natural History of Geographic Atrophy (2009) What's New in Age-related Macular Degeneration, Baltimore, MD

Sung JU. Laser management of vein occlusive disease (2008) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU. Management of geography atrophy (2008) What's New in Age-related Macular Degeneration, Baltimore, MD

Sung JU Neuroprotection and the Retina (2008) Grand Rounds Invited Speaker, UCLA, Jules Stein Eye Institute, Los Angeles, CA

Sung JU. Sustained-release agents for macular edema from venous occlusive disease (2007) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU. Intravitreal agents and impact on practice management (2007) What's New in Age-related Macular Degeneration, Baltimore, MD

Sung JU. Other therapies for diabetic retinopathy (2006) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU, Shah SM, Do DV, Nguyen QD, Tatlipinar S, Haller J, Quinlan E, Zimmer-Galler I, and Campochiaro P. Ranibizumab for edema of the macula in diabetes (READ): One year interim results. (2006) Retina Society, Capetown, South Africa

Sung JU. Surgery for vein occlusion (2005) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU. Surgery for Vein Occlusion (2004) What's New in Diabetic Retinopathy and Venous Occlusive Disease, Baltimore, MD

Sung JU Neuroprotection and the Retina (2004) Grand Rounds Invited Speaker, Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, OH

Sung JU, Lima e Silva R, Saishin Y, Zhang, M, Rogers B, Deering T, Aslam S, Saishin Y, Campochiaro PA. The effect of erythropoietin on hyperoxia-induced retinal degeneration and hypoxia-induced retinal neovascularization. (2004) ARVO, Fort Lauderdale, FL

Sung JU. Treatment of Age-related Macular Degeneration. (2004) JCAHPO, New Orleans, LA

Sung JU Surgery for vein occlusions. (2003) Current Concepts in Ophthalmology, Baltimore, MD

JENNIFER U. SUNG

Sung J, Okoye G, Zimmer J, Gehlbach P, Deering T, Nambu H, Hackett S, Melia M, Esumi N, Zack DJ, Campochiaro PA. Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. (2003) ARVO, Fort Lauderdale, FL

Sung JU Neuroprotection and the retina. (2002) Current Concepts in Ophthalmology, Baltimore, MD

Sung JU. New treatments for macular edema. (2001) Current Concepts in Ophthalmology, Baltimore, MD

Sung J, Federman J. Silicone oil in the management of pediatric traumatic retinal detachments. (2000) Fifth International symposium for ocular trauma. Montreal, Canada.

Sung J, Tasman W. (1999) Fluorescein angiography of macular changes in neonates with retinopathy of prematurity. Retina Society, Maui, HI

Sung J, Flynn H, Jr, Ehliel F. (1998) Etiology and echographic features of choroidal folds. Bascom Palmer Eye Institute 34th Annual Residents' Days, Coral Gables, FL.

Sung J, Rubsamen P, Murray T, Smiddy W, Rosenfeld R, Feuer W, and Flynn H, Jr. (1997) Outcomes in subfoveal surgery for subretinal neovascular membranes. Bascom Palmer Eye Institute 33rd Annual Residents' Days, Coral Gables, FL.

Sung J, Lam B, Curtin V, Rosa R, Tse D, Schatz N, and Jillapalli D. (1997) Unilateral visual loss in metastatic gastric carcinoma to the optic nerve. Frank A. Walsh Society Meeting, Baltimore, MD.

Sung J, Aaberg T, Jr, and Lewis M. (1996) Clinical course of juxtafoveal retinal telangiectasis-related neovascular membranes. Bascom Palmer Eye Institute 32nd Annual Residents' Days, Coral Gables, FL.

CLINICAL TRIALS:

Co-Investigator - Diabetic Retinopathy Clinical Research Network

Co-Investigator - Ranibizumab for Diabetic Macular Edema

Co-Investigator - Ranibizumab for Venous Occlusive Disease

Co-Investigator - The Genetics of Macular Degenerations

Co-Investigator - Safety and Efficacy of VEGF-trap in Patients with Exudative Age-Related Macular Degeneration

Co-Investigator - Safety and Efficacy of Combretastatin in Patients with Exudative Age-Related Macular Degeneration

Co-Investigator - Safety and Efficacy of Intravitreal Injections of RhuFab in Patients with Exudative Age-Related Macular Degeneration

Co-Investigator - Safety and Efficacy of Intravitreal Injections of EYE001(Anti-VEGF Pegylated Aptamer), in Patients with Exudative Age-Related Macular Degeneration

Co-Investigator - Supplemental Inspired Oxygen

Co-Investigator - Study of ADgVPEDF.11D in Neovascular AMD

Co-Investigator - Oculex - Trial to Assess the Safety and Efficacy of Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in the treatment of PME

TEACHING EXPERIENCE:

Johns Hopkins University School of Medicine – Medical students' lectures, tutorials, elective clerkship rotations

Wilmer Eye Institute – Ophthalmology residents' lectures, clinical rotations, vitreoretinal fellows' teaching conferences, clinical and surgical rotations

Greater Baltimore/Washington, DC Metropolitan area – Patient-oriented lectures on retinal diseases including age-related macular degeneration and diabetic retinopathy.

JENNIFER U. SUNG

ADMINISTRATIVE EXPERIENCE:

2001-2004 Medical Director, Wilmer Eye Institute at Rockville. Experience with growing a retina practice in a satellite location, hiring and training staff and other administrative duties.

BOARD CERTIFICATION:

1999 American Board of Ophthalmology
2009 ABO recertification

MEDICAL LICENSURE:

California
Maryland (inactive)
Pennsylvania (inactive)
Florida (inactive)

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

1997-present American Academy of Ophthalmology
2000-present Association for Research in Vision and Ophthalmology
2001-present American Society of Retina Specialists
2006-present The Retina Society
1998-2001 Pennsylvania Academy of Ophthalmology
1995-98 Miami Ophthalmological Society
1993-94 Phi Rho Sigma

EDITORIAL BOARD:

Ophthalmology, Ad Hoc Reviewer
Archives of Ophthalmology, Ad Hoc Reviewer

ACTIVITIES and INTERESTS:

Piano, flute, and voice
Traditional Korean dance, ballet, contemporary
Travel, international cuisine, reading, swimming, tennis
Foreign languages: Korean, French, and Spanish

MARITAL STATUS:

Spouse, Sherwin Hua, M.D., PhD., Neurosurgeon, Neurosurgical Associates of Los Angeles

CHILDREN:

Alexa Hua, age 6 years
Ava Hua, age 3